A real‐world comparison of docetaxel versus abiraterone acetate for metastatic hormone‐sensitive prostate cancer

Background Docetaxel (D) or secondary hormonal therapy (SHT) each combined with androgen deprivation therapy (ADT) represent possible treatment options in males with metastasized hormone‐sensitive prostate cancer (mHSPC). Real‐world data comparing different protocols are lacking yet. Thus, our objec...

Full description

Saved in:
Bibliographic Details
Published in:Cancer medicine (Malden, MA) MA), 2021-09, Vol.10 (18), p.6354-6364
Main Authors: Tsaur, Igor, Heidegger, Isabel, Bektic, Jasmin, Kafka, Mona, Bergh, Roderick C. N., Hunting, Jarmo C. B., Thomas, Anita, Brandt, Maximilian P., Höfner, Thomas, Debedde, Eliott, Thibault, Constance, Ermacora, Paola, Zattoni, Fabio, Foti, Silvia, Kretschmer, Alexander, Ploussard, Guillaume, Rodler, Severin, Amsberg, Gunhild, Tilki, Derya, Surcel, Christian, Rosenzweig, Barak, Gadot, Moran, Gandaglia, Giorgio, Dotzauer, Robert
Format: Article
Language:English
Subjects:
Abiraterone Acetate - therapeutic use
Acetic acid
Aged
Androgen Antagonists - therapeutic use
Antigens
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Cancer therapies
chemotherapy
Clinical Cancer Research
Clinical outcomes
Docetaxel - therapeutic use
hormonal therapy
hormone‐sensitive
Humans
Male
Metastases
Metastasis
Middle Aged
Progression-Free Survival
Prostate cancer
Prostatic Neoplasms, Castration-Resistant - drug therapy
Prostatic Neoplasms, Castration-Resistant - mortality
Prostatic Neoplasms, Castration-Resistant - pathology
Retrospective Studies
Statistical analysis
Survival
Survival analysis
Toxicity
Variables
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Docetaxel (D) or secondary hormonal therapy (SHT) each combined with androgen deprivation therapy (ADT) represent possible treatment options in males with metastasized hormone‐sensitive prostate cancer (mHSPC). Real‐world data comparing different protocols are lacking yet. Thus, our objective was to compare the efficacy and safety of abiraterone acetate (AA)+ADT versus D+ADT in mHSPC. Methods In a retrospective multicenter analysis including males with mHSPC treated with either of the aforementioned protocols, overall survival (OS), progression‐free survival 1 (PFS1), and progression‐free survival 2 (PFS2) were assessed for both cohorts. Median time to event was tested by Kaplan–Meier method and log‐rank test. The Cox‐proportional hazards model was used for univariate and multivariate regression analyses. Results Overall, 196 patients were included. The AA+ADT cohort had a longer PFS1 in the log‐rank testing (23 vs. 13 mos., p 
ISSN:2045-7634
2045-7634
DOI:10.1002/cam4.4184